How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer

Journal of Clinical Oncology

Volumn 31, Issue 29, 2013, Pages 3618-3620

  Haddad, Robert I ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; PONATINIB; VANDETANIB; ANILIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MEDULLARY THYROID CANCER; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; THYROID CANCER; TORSADE DES POINTES; FEMALE; MALE; NOTE; THYROID TUMOR; THYROID NEOPLASMS;

ANILIDES; FEMALE; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS;

EID: 84891603306     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5098     Document Type: Review

References (9)

1. Wells SA Jr, Pacini F, Robinson BG, et al: Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: An update. J Clin Endocrinol Metab [epub ahead of print on June 6, 2012]
2. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, doubleblind phase III trial. J Clin Oncol 30:134-141, 2012
3. Elisei R, Schlumberger MJ, Müller SP, et al: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639-3646, 2013
4. Kurzrock R, Sherman SI, Ball DW, et al: Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666, 2011
5. Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 31:412-419, 2013
6. Yang J, Mehrotra N, Zhao H, et al: Characterization of the exposureresponse relationship leading to recommendations for dosing optimization in a new drug application review. J Clin Oncol 31:143s, 2013 (suppl; abstr 2510)
7. Barbet J, Campion L, Kraeber-Bodéré F, et al: Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084, 2005 (Pubitemid 41606528)
8. Sherman S, Cohen E, Schoffski P, et al: Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. J Clin Oncol 31:363s,, 2013 (suppl; abstr 6000)
9. Gozgit JM, Chen T-H, Clackson T, et al: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC. 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, April 6-10, 2013 (abstr 2084)